Key facts
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Amrixa Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Amrixa Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Amrixa Pharmaceuticals
Developer of mRNA-LNP therapeutics intended to treat diseases that currently lack effective medical options. The company's platform uses proprietary mRNA sequences, lipid nanoparticle formulations, and established manufacturing methods to create targeted therapeutics designed for controlled delivery, preclinical validation, and potential clinical translation in under-served disease areas.
- Sector
- Healthcare
- HQ
- San Marcos, CA, United States
- Founded
- 2024
- Website
- amrixapharmaceuticals.com/
- Ownership
- Privately Held (backing)
Amrixa Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amrixa Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amrixa Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.